[Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases].

Abstract	TNFalpha plays a crucial role in the physiopathology of a large number of auto-immune and/or inflammatory systemic diseases. In addition to authorized indications including rheumatoid arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, psoriatic arthritis and plaque psoriasis, TNFalpha blockers have been tested in a wide range of auto-immune and/or inflammatory diseases. TNFalpha blockers might be an option in refractory ANCA-associated vasculitis, sarcoïdosis, adult onset Still disease, Behçet disease, AA amyloïdosis and TRAPS. However, pertaining to the limited number of prospective randomized trails available, the small number of patients included and the poor methodology, it is difficult to define their place in the therapeutic strategy in these conditions. The therapeutic effect of TNFalpha blockers is often suspensive and disease flares are frequently observed during sustained treatment, as in the case of Behçet's disease. Published data do not support the use of TNFalpha blockers in connective tissue diseases.
Authors	Alexis Régent, Luc Mouthon
Journal	Presse medicale (Paris, France : 1983) (Presse Med) Vol. 38 Issue 5 Pg. 761-73 (May 2009) ISSN: 2213-0276 [Electronic] France
Vernacular Title	Traitements anti-TNFalpha dans les maladies auto-immunes et/ou inflammatoires systémiques.
PMID	19349142 (Publication Type: English Abstract, Journal Article)
Chemical References	Anti-Inflammatory Agents Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antirheumatic Agents Immunoglobulin G Immunosuppressive Agents Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha Infliximab Adalimumab Etanercept Methotrexate
Topics	Adalimumab Anti-Inflammatory Agents (therapeutic use) Antibodies, Monoclonal (therapeutic use) Antibodies, Monoclonal, Humanized Antirheumatic Agents (therapeutic use) Autoimmune Diseases (drug therapy) Etanercept Humans Immunoglobulin G (therapeutic use) Immunosuppressive Agents (therapeutic use) Inflammation (drug therapy) Infliximab Methotrexate (therapeutic use) Receptors, Tumor Necrosis Factor (therapeutic use) Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!